Versavo+ 400 mg Infusion 16 ml is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer can start in one region of the body and spread to other parts. This is referred to as metastasis.

Versavo+ 400 mg Infusion 16 ml contains 'Bevacizumab' that works against vascular endothelial growth factor (VEGF) which is found on the lining of lymph and blood vessels. VEGF causes blood vessels to grow within tumours which provide oxygen and nutrients to the tumour. Inhibition of vascular endothelial growth factor limits the flow of oxygen and nutrients to the tumour, causing it to shrink or cease developing. Thus, it helps treat cancers.

Versavo+ 400 mg Infusion 16 ml will be administered by a healthcare professional; do not self-administer. Based on your medical condition, your doctor will decide the dose and duration. In some cases, Versavo+ 400 mg Infusion 16 ml may cause loss of appetite, constipation, fever, nosebleeds, change in speech, and taste. The majority of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen

Avoid taking Versavo+ 400 mg Infusion 16 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Versavo+ 400 mg Infusion 16 ml may cause sleepiness and fainting, so avoid driving while on treatment with Versavo+ 400 mg Infusion 16 ml. Do not breastfeed during the treatment and for 6months after the last dose of Versavo+ 400 mg Infusion 16 ml. Keep your doctor informed about your health condition and all the medicines you take to rule out any side effects.

Versavo+ 400 mg Infusion 16 ml contains Bevacizumab, a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Versavo+ 400 mg Infusion 16 ml works against a protein called vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) inhibition limits the flow of oxygen and nutrients to the tumour cells, causing them to shrink or cease developing. Thus, it helps treat cancer.

Versavo+ 400 mg Infusion 16 ml should only be taken under medical supervision. While taking Versavo+ 400 mg Infusion 16 ml, the doctor will monitor your condition on a regular basis. If you have a history of allergic reactions to Versavo+ 400 mg Infusion 16 ml or other medications, inform your doctor before taking it. Avoid taking Versavo+ 400 mg Infusion 16 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Versavo+ 400 mg Infusion 16 ml may cause sleepiness and fainting, so avoid driving while on treatment with Versavo+ 400 mg Infusion 16 ml. Inform your doctor if you have/had high blood pressure, heart attack, stroke, bleeding problems, stomach/intestinal bleeding, perforation; if you had surgery in the past 28days/are due to have surgery. Do not breastfeed during the treatment and for 6months after the last dose of Versavo+ 400 mg Infusion 16 ml. While taking Versavo+ 400 mg Infusion 16 ml, please do not get any immunizations or vaccinations unless your doctor has approved it. Versavo+ 400 mg Infusion 16 ml may increase the risk of bleeding, so be cautious and consult your doctor if you notice any bleeding or bruising.